Versions
- 2021-11-14 (2)
- 2019-12-17 (1)
Keywords
RP-HPLC
Validation
ICH guidelines
UV Spectrophotometry
How to Cite
Abstract
Recent study was conducted to develop and validate analytical methods for estimation of Risedronate sodium in pure and pharmaceutical dosage form using UV Spectroscopy and               RP- HPLC method. The first method (Method A) based on the UV Spectroscopy using 0.1M Hcl as diluent lambda max was found at 261 nm. Linearity existed perceived in the concentration between 10-50 μg/ml (r 2 = 0.999) for the method. The method was validated pertaining to linearity, precision and accuracy studies, LOD and LOQ consistent with ICH guidelines. The second method (Method B), based on determination of Risedronate sodium tablet dosage form by RP-HPLC method.  Chromatography separation was carried out on a C18 (150X4.6 mm x5 µ) SS Column using Methanol: Ammonium formate (85:15) as the mobile phase at a flow rate of   1.0 ml/min. The chromatographic analysis was carried out in the reflectance and absorbance mode at 254 nm and retention time of the drug was found to be 1.11 ml/min for standard and tablet. Linear responses of the drug were in the concentration range of 200-1000 µg/ml. The accuracy of the method was assessed by standard dilution method and found to be 98% to              102% .The results of the analysis were validated statistically prism software. The method established was found to be simple, precise, linear, accurate and sensitive. The developed method can be used for routine quality control analysis of Risedronate sodium in pure and pharmaceutical dosage form.References
European Pharmacopoeia. 4 ed.; (EDQM), E. D. f. Q. o. M., Ed. European Council: Strasbourg, 2002, pp 1661-1662.
Indian Pharmacopoeia. (IPC), I. P. C., Ed. Government of India: Ghaziabad, 1996, pp 2789-2791.
Crandall, C. Risedronate: A Clinical Review. Arch Intern Med 2001, 161 (3), 353-360.
https://doi.org/10.1001/archinte.161.3.353
Vallano, P. T.; Shugarts, S. B.; Kline, W. F.; Woolf, E. J.; Matuszewski, B. K. Determination of risedronate in human urine by column-switching ion-pair high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B 2003, 794 (1), 23-33.
https://doi.org/10.1016/S1570-0232(03)00394-5
Ghassabian, S.; Wright, L. A.; deJager, A. D.; Smith, M. T. Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma. Journal of Chromatography B 2012, 881-882, 34-41.
https://doi.org/10.1016/j.jchromb.2011.11.031
Walash, M. I.; Metwally, M. E. S.; Eid, M.; El-Shaheny, R. N. Spectrophotometric Determination of Risedronate in Pharmaceutical Formulations via Complex Formation with Cu (II) Ions: Application to Content Uniformity Testing. International journal of biomedical science : IJBS 2008, 4 (4), 303-309.
Walash, M. I.; Metwally, M. E. S.; Eid, M. I.; El-Shaheny, R. N. Spectrophotometric Determination of Risedronate and Etidronate in Pharmaceutical Formulations via the Molybdovanadate Method. Anal Lett 2009, 42 (11), 1571-1587.
https://doi.org/10.1080/00032710902993795
Committee, I. C. H. S., ICH Q2A Text on Validation of Analytical Procedures (CPMP/ICH/381/95). European Agency for the Evaluation of Medicinal Products, International Commission on Harmonisation: London, 1994.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.